[{"from": "human", "value": "Provide a description of this molecule. [C][C@H1][Branch1][S][C][=C][Branch1][O][C][=C][C][=Branch1][Branch1][=C][Ring1][=Branch1][Cl][F][Cl][O][C][=C][Branch2][Ring1][#Branch2][N][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][C][=C][N][Branch1][Branch1][N][=C][Ring1][Branch1][C][C][C][N][C][C][Ring1][=Branch1][N]"}, {"from": "gpt", "value": "The molecule is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements."}]